Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 5.2 %

EGRX opened at $5.50 on Friday. The company’s fifty day moving average price is $4.25 and its two-hundred day moving average price is $4.93. Eagle Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $23.52. The company has a market cap of $71.45 million, a price-to-earnings ratio of 4.66 and a beta of 0.50.

Institutional Trading of Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in EGRX. Headlands Technologies LLC raised its holdings in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Eagle Pharmaceuticals by 623.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 5,896 shares during the last quarter. DGS Capital Management LLC purchased a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $60,000. Price T Rowe Associates Inc. MD purchased a new stake in Eagle Pharmaceuticals during the first quarter worth about $83,000. Finally, Aristides Capital LLC purchased a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $86,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.